When a little aspirin may be enough

Blood

Volumn 119, Issue 4, 2012, Pages 905-906

  Kastritis, Efstathios ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 8; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ENOXAPARIN; ERYTHROPOIETIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; POMALIDOMIDE; PREDNISONE; THALIDOMIDE; THROMBIN INHIBITOR; THROMBOPLASTIN; VON WILLEBRAND FACTOR; WARFARIN;

ARTERIAL THROMBOEMBOLISM; ARTERY EMBOLISM; ARTERY THROMBOSIS; CENTRAL NERVOUS SYSTEM DISEASE; DRUG ANTAGONISM; DRUG MEGADOSE; GENETIC POLYMORPHISM; GROUPS BY AGE; HEREDITY; HUMAN; IMMOBILIZATION; LOW DRUG DOSE; LUNG EMBOLISM; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROTOXICITY; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SUPERFICIAL THROMBOPHLEBITIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 84856287364     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-375089     Document Type: Note

References (12)

1. Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119(4):933-939.
2. Kristinsson SY, Pfeiffer RM, Bjorkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115(24):4991-4998.
3. Falanga A, MarchettiM.Venousthromboembolismin the hematologic malignancies.JClin Oncol. 2009;27(29):4848-4857.
4. Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol. 2009;145(2):151-163.
5. van Marion AM, Auwerda JJ, Lisman T, et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res. 2008;32(7):1078-1084.
6. Valsami S, Ruf W, Leikauf MS, Madon J, Kaech A, Asmis LM. Immunomodulatory drugs increase endothelial tissue factor expression in vitro. Thromb Res. 2011;127(3): 264-271.
7. Johnson DC, Corthals S, Ramos C, et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood. 2008;112(13):4924-4934.
8. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29-37.
9. Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood. 2010; 116(26):5838-5841.
10. Zangari M, Tricot G, Polavaram L, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol. 2010;28(1):132-135.
11. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414-423. (Pubitemid 351255436)
12. Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29(8): 986-993.